Results 191 to 200 of about 4,421,151 (391)
TRPM8 levels determine tumor vulnerability to channel agonists
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo+18 more
wiley +1 more source
Measuring Health‐Related Quality of Life Among Patients Infected with Human Immunodeficiency Virus
Diane Franchi, Richard P. Wenzel
openalex +1 more source
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer [PDF]
John T. Wei+4 more
openalex +1 more source
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte+10 more
wiley +1 more source
The impact of chronic diseases on the health-related quality of life (HRQOL) of Chinese patients in primary care [PDF]
C. L. Lam, I Lauder
openalex +1 more source
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song+11 more
wiley +1 more source
Health-related quality of life in outpatients with COPD in daily practice: the VICE Spanish study
Antonio Martín1, José M Rodríguez-González Moro2, José L Izquierdo3, Elena Gobartt4, Pilar de Lucas2, The VICE Study Group1Medical Department, Pfizer, Madrid, Spain; 2Service of Pneumology, HGU ...
Antonio Martín+5 more
doaj
O. Ethgen+4 more
semanticscholar +1 more source
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source
Alina Deniza Ciubean,1,2 Rodica Ana Ungur,2,3 Laszlo Irsay,2,3 Viorela Mihaela Ciortea,2,3 Ileana Monica Borda,2,3 Ioan Onac,2,3 Stefan Cristian Vesa,1 Anca Dana Buzoianu1 1Department of Pharmacology, Toxicology and Clinical Pharmacology, Iuliu ...
Ciubean AD+7 more
doaj